18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.
暂无分享,去创建一个
Chris Sander | Hong Wu | Michael E Phelps | Evangelia Komisopoulou | Nikolaus Schultz | Richard Taschereau | Ingo K Mellinghoff | Cameron Brennan | Adriana Heguy | Steven M Larson | Carl Campos | C. Sander | R. Taschereau | C. Brennan | N. Schultz | S. Larson | T. Graeber | J. Huse | I. Mellinghoff | M. Phelps | A. Heguy | D. Rohle | J. Osborne | E. Port | Edward R. Kastenhuber | Hong Wu | C. Tran | Carl Campos | E. Komisopoulou | Nicolaos J Palaskas | S. Plaisier | J. Wong | Jason T Huse | I. Linkov | Nicolaos Palaskas | Chris Tran | Elisa Port | Thomas G Graeber | Dan Rohle | Joseph R Osborne | Edward R Kastenhuber | Nicolas Yannuzzi | Justin Wong | Irina Linkov | Seema B Plaisier | Nicolas A. Yannuzzi | N. Palaskas | Evangelia Komisopoulou | Nicolaos J. Palaskas
[1] R A Jungmann,et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[2] Ash A. Alizadeh,et al. Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.
[3] K. Gulenchyn,et al. Is there a role for positron emission tomography in breast cancer staging? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Jorge S Reis-Filho,et al. Triple-negative breast cancer. , 2010, The New England journal of medicine.
[5] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[6] Guido Kroemer,et al. Tumor cell metabolism: cancer's Achilles' heel. , 2008, Cancer cell.
[7] A. Elster,et al. Recommendations on the Use of 18F-FDG PET in Oncology , 2009 .
[8] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[9] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[10] I. Buvat,et al. Partial-Volume Effect in PET Tumor Imaging* , 2007, Journal of Nuclear Medicine.
[11] M. Cole,et al. A Functional Screen for Myc-Responsive Genes Reveals Serine Hydroxymethyltransferase, a Major Source of the One-Carbon Unit for Cell Metabolism , 2002, Molecular and Cellular Biology.
[12] L. Cantley,et al. Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.
[13] T. Golub,et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.
[14] Sarah A. Pendergrass,et al. A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response , 2009, PloS one.
[15] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[16] S. Dry,et al. PTEN dosage is essential for neurofibroma development and malignant transformation , 2009, Proceedings of the National Academy of Sciences.
[17] E. Lander,et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[18] C. Dang,et al. MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities , 2009, Clinical Cancer Research.
[19] Ingo K Mellinghoff,et al. Tracing cancer networks with phosphoproteomics , 2010, Nature Biotechnology.
[20] A. Alavi,et al. Comparison of triple‐negative and estrogen receptor‐positive/progesterone receptor‐positive/HER2‐negative breast carcinoma using quantitative fluorine‐18 fluorodeoxyglucose/positron emission tomography imaging parameters , 2008, Cancer.
[21] A. Karmoliński,et al. Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue. , 2001, Clinical biochemistry.
[22] Howard Y. Chang,et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[23] L. Saal,et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair , 2008, Nature Genetics.
[24] Renu M. Stephen,et al. Regulation of the Warburg effect in early-passage breast cancer cells. , 2008, Neoplasia.
[25] Hanina Hibshoosh,et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.
[26] D. Mankoff,et al. Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer , 2010, Clinical Cancer Research.
[27] David J. Nott,et al. Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup , 2009, PloS one.
[28] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[29] N. Isern,et al. c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry , 2009, Oncogene.
[30] Duonan Yu,et al. Functional Validation of Genes Implicated in Lymphomagenesis: An in Vivo Selection Assay Using a Myc‐Induced B‐Cell Tumor , 2005, Annals of the New York Academy of Sciences.
[31] U. Alon,et al. Just-in-time transcription program in metabolic pathways , 2004, Nature Genetics.
[32] R. Taschereau,et al. Rank–rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures , 2010, Nucleic acids research.
[33] N. Hynes,et al. Key signalling nodes in mammary gland development and cancer: Myc , 2009, Breast Cancer Research.
[34] W. Kaelin,et al. Q&A: Cancer: Clues from cell metabolism , 2010, Nature.
[35] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[36] M. Schwaiger,et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] T. Graeber,et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.
[38] Jan Ihmels,et al. Principles of transcriptional control in the metabolic network of Saccharomyces cerevisiae , 2004, Nature Biotechnology.
[39] Tsung-Cheng Chang,et al. c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.
[40] Anthony Mancuso,et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.
[41] M. Schwaiger,et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] U. Weidle,et al. The transcriptional program of a human B cell line in response to Myc. , 2001, Nucleic acids research.
[43] Ajay N. Jain,et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.
[44] Howard Y. Chang,et al. Genetic regulators of large-scale transcriptional signatures in cancer , 2006, Nature Genetics.
[45] T. Waldman,et al. PTEN Gene Targeting Reveals a Radiation-Induced Size Checkpoint in Human Cancer Cells , 2004, Cancer Research.
[46] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[47] A. Alavi,et al. 18F-FDG Uptake in Lung, Breast, and Colon Cancers: Molecular Biology Correlates and Disease Characterization* , 2009, Journal of Nuclear Medicine.
[48] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[49] Kathryn A. O’Donnell,et al. Activation of Transferrin Receptor 1 by c-Myc Enhances Cellular Proliferation and Tumorigenesis , 2006, Molecular and Cellular Biology.
[50] Norhanom Abdul Wahab,et al. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. , 2002, International journal of molecular medicine.
[51] O. Warburg. On the origin of cancer cells. , 1956, Science.
[52] Yoshihiro Yamanishi,et al. KEGG for linking genomes to life and the environment , 2007, Nucleic Acids Res..
[53] R. L. Baldwin,et al. Gene expression in epithelial ovarian carcinoma , 2002, Oncogene.
[54] Robert Tibshirani,et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.
[55] M. Ringnér,et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.